Lucid Diagnostics Inc (LUCD) said after close Monday that it lost $0.23 per share in quarter four 2023. The company reported earnings on an adjusted basis, so it may not be directly comparable to analyst estimates or prior periods.
On the revenue line, the company reported $1 million, missing estimates by $10 thousand.
In the same quarter a year ago, the company lost $0.15 per share on revenue of $112 thousand.
The stock is down 6.32% to $0.99 after the report.
The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.
The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.
Trading in the five days leading up to the report earned Lucid Diagnostics Inc a Neutral Sentiment Rank from InvestorsObserver.
Lucid Diagnostics Inc has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 4, putting Lucid Diagnostics Inc in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $0.99 on March 20, 2024 and set a 52-week high on June 5, 2023 at $1.85.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
News Home
Lucid Diagnostics Inc Down 6.32% To $0.99 After Earnings Beat
Mentioned in this article
